当辉瑞在2月4日的财报电话会上宣布计提29亿美元无形资产减值时，市场的目光再次聚焦ADC赛道。 其中，10亿美元的“沉没成本”，直指其B7-H4 ADC药物Felmetatug vedotin的研发终止。B7-H4，这个曾被寄予厚望的ADC新兴靶点，再次迎来一大挫折。 尽管Felmetatug vedotin早期 ...

其中，10亿美元的“沉没成本”，直指其B7-H4 ADC药物Felmetatug vedotin的研发终止。B7-H4，这个曾被寄予厚望的ADC新兴靶点，再次迎来一大挫折。 尽管 ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed ...

H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...

NextCure, Inc. has completed cohort 1 of the Phase 1 trial for its cancer treatment candidate, LNCB74 (B7-H4 ADC), in February 2025 and plans to initiate backfill cohorts later in the year.

Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the ...